Association of diffuse, random pulmonary metastases, including miliary metastases, with epidermal growth factor receptor mutations in lung adenocarcinoma

Cancer

Volumn 117, Issue 4, 2011, Pages 819-825

  Togashi, Yosuke ^a   Masago, Katsuhiro ^a   Kubo, Takeshi ^a   Sakamori, Yuichi ^a   Kim, Young Hak ^a   Hatachi, Yukimasa ^a   Fukuhara, Akiko ^a   Mio, Tadashi ^a   Togashi, Kaori ^a   Mishima, Michiaki ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

epidermal growth factor receptor gene mutation; lung cancer; miliary metastases; pulmonary metastases; tyrosine kinase inhibitor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CIGARETTE SMOKING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE MUTATION; HUMAN; JAPANESE; LUNG ADENOCARCINOMA; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; SMOKING HABIT; TUMOR LOCALIZATION; TUMOR VOLUME; WILD TYPE; EGFR GENE; JAPANESE (PEOPLE); LUNG NODULE; MEDICAL HISTORY; MUTATIONAL ANALYSIS; SMOKING;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; FEMALE; GENES, ERBB-1; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; NEOPLASM METASTASIS; QUINAZOLINES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79551709963     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25618     Document Type: Article

References (22)

1. Baselga J, Arteaga CL., Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol. 2005; 23: 2445-2459.
2. Jackman DM, Yeap BY, Sequist LV, et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in nonsmall cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res. 2006; 12: 3908-3914.
3. Riely GJ, Pao W, Pham D, et al. Clinical course of patients with nonsmall cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2006; 12: 839-844.
4. Yamamoto H, Toyooka S, Mitsudomi T., Impact of EGFR mutation analysis in nonsmall cell lung cancer. Lung Cancer. 2009; 63: 315-321.
5. Herold CJ, Bankier AA, Fleischmann D., Lung metastases. Eur Radiol. 1996; 6: 596-606.
6. Park K, Goto K., A review of the benefit-risk profile of gefitinib in Asian patients with advanced nonsmall-cell lung cancer. Curr Med Res Opin. 2006; 22: 561-573.
7. Masago K, Asato R, Fujita S, et al. Epidermal growth factor receptor gene mutations in papillary thyroid carcinoma. Int J Cancer. 2009; 124: 2744-2749.
8. Nagai Y, Miyazawa H, Huqun, et al. Genetic heterogeneity of the epidermal growth factor receptor in nonsmall cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res. 2005; 65: 7276-7282.
9. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T., Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res. 2004; 64: 8919-8923.
10. Hansell DM, Bankier AA, MacMahon H, McLoud TC, Muller NL, Remy J., Fleischner Society: glossary of terms for thoracic imaging. Radiology. 2008; 246: 697-722.
11. Mitsudomi T, Yatabe Y., Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci. 2007; 98: 1817-1824.
12. Toyooka S, Matsuo K, Shigematsu H, et al. The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non small cell lung cancer. Clin Cancer Res. 2007; 13: 5763-5768. (Pubitemid 47583901)
13. Lee KS, Kim TS, Han J, et al. Diffuse micronodular lung disease: HRCT and pathologic findings. J Comput Assist Tomogr. 1999; 23: 99-106.
14. Xu Y, Liu YJ, Yu Q., Angiopoietin-3 inhibits pulmonary metastasis by inhibiting tumor angiogenesis. Cancer Res. 2004; 64: 6119-6126.
15. Mitsudomi T, Yatabe Y., Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J. 2010; 277: 301-308.
16. De Luca A, Carotenuto A, Rachiglio A, et al. The role of the EGFR signaling in tumor microenvironment. J Cell Physiol. 2008; 214: 559-567.
17. Tanaka T, Nagai Y, Miyazawa H, et al. Reliability of the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations integrated into the clinical practice for nonsmall cell lung cancers. Cancer Sci. 2007; 98: 246-252.
18. Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced nonsmall-cell lung cancer. J Clin Oncol. 2004; 22: 1103-1109.
19. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med. 2004; 350: 2129-2139.
20. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004; 101: 13306-13311.
21. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005; 97: 339-346. (Pubitemid 40425952)
22. Motoi N, Szoke J, Riely GJ, et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol. 2008; 32: 810-827.